The MHRA has used AdvaMed 2026 to signal that AI medical device policy is moving from broad statements to an operational programme. In its press release published on 19 October 2026, the regulator said Jessica Paulsen, Deputy Director for AI and Software, would use her 20 October conference appearance to set out work on software and AI-enabled medical devices built around lifecycle regulation, regulatory sandboxes and closer international cooperation. (gov.uk) That presentation is not a new policy document in itself. It is better read as a public marker that the MHRA now intends to apply its recent AI policy work through live testing, post-market evidence and regulator-to-regulator contact. (gov.uk)
Much of the detail sits within the MHRA 2030 Strategy, published on 14 October 2026. The strategy commits the regulator to create an adaptive framework for AI as a medical device, establish an MHRA Centre for AI and Digital Health, improve device data and traceability, and expand reliance and recognition routes with trusted regulators, including the US Food and Drug Administration. (gov.uk) The same strategy states an ambition for the MHRA to set a global standard for safe and agile MedTech and AI regulation by 2030 while supporting faster access to innovation. In that context, the AdvaMed intervention functions less as a standalone announcement and more as an external briefing on reforms already entering implementation. (gov.uk)
The government has already reinforced that direction. In a response published on 6 October 2026, it accepted all 44 recommendations from the independent National Commission into the Regulation of AI in Healthcare, whose central conclusion was that regulation and assurance should become more proportionate, lifecycle-based and system-wide. (gov.uk) For developers and NHS organisations, that points to a framework in which evidence generation does not stop at pre-market assessment. The Commission’s report placed particular weight on clearer rules for post-market evaluation, monitoring and the boundary between research, service evaluation and clinical governance. (gov.uk)
The MHRA is testing that model through the AI Airlock, launched in 2024 and now in its third phase, and through regional NHS partnerships in London and Manchester. GOV.UK material describes these sandboxes as controlled settings in which AI-enabled medical devices can be deployed in real clinical environments to generate evidence under MHRA oversight. (gov.uk) This is one of the more concrete elements of the current reform programme. It gives manufacturers a route to test questions that conventional regulatory submissions do not always resolve, while giving the regulator and NHS partners better data on performance, safety and deployment conditions before wider adoption. (gov.uk)
International coordination forms the second pillar. The MHRA said its MHRA-FDA Pioneer Programme, announced in June 2026, creates reciprocal liaison roles intended to deepen day-to-day cooperation, scientific exchange and coordination on emerging issues, including AI and medical devices, while leaving both agencies to make their own regulatory decisions. (gov.uk) The agency is also recruiting a Regional Deputy Director of US Partnerships in Washington, DC to serve as its dedicated FDA liaison. For companies planning UK and US market entry, the practical value lies in earlier regulatory contact and a better chance of aligned expectations, even though the arrangement does not create joint approvals or automatic market access. (gov.uk)
The wider legal backdrop is still being assembled. On 1 September 2026, the government tabled Health Bill amendments covering information-sharing powers, a quicker route to update medicines and medical device legislation, and enabling powers for a future medical device licensing regime. The MHRA has been clear that these proposals do not create immediate rule changes and would still need further policy development, consultation and parliamentary scrutiny. (gov.uk) That point is easy to miss in headline announcements. The reform package is substantial, but part of it remains contingent on legislation and later secondary rules, so manufacturers, NHS providers and advisers still need to monitor several parallel workstreams. (gov.uk)
Taken together, the AdvaMed message is that the MHRA wants AI medical device regulation to be adaptive, evidence-led and more closely tied to real-world use than a model focused mainly on pre-market assessment. The regulator is pairing that aim with NHS-based testing, closer FDA engagement and a legislative programme designed to keep technical rules up to date. (gov.uk) The remaining question is delivery. The policy direction is now clearly signalled across the 19 October 2026 AdvaMed press release, the 14 October 2026 MHRA 2030 Strategy and the 6 October 2026 government response to the AI Commission; the harder task is turning those commitments into clearer routes for market entry, post-market surveillance and patient protection. (gov.uk)